Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGOBSERVATIONAL

Russian Extreme Hypertriglyceridemia Registry

Russian Extreme Hypertriglyceridemia Registry (REGGI)

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

The REGGI registry is a prospective, multicenter observational registry in Russia designed to collect data on patients with extreme hypertriglyceridemia (triglyceride levels ≥10 mmol/L). The registry aims to describe the clinical, demographic, and molecular-genetic characteristics of patients, as well as current diagnostic approaches and treatment patterns in real-world practice. The collected data may inform future research and support improvements in patient care.

Who May Be Eligible (Plain English)

Who May Qualify: - Patients with extreme hypertriglyceridemia (triglyceride levels ≥10 mmol/L), confirmed by at least two independent measurements. - Written willing to sign a consent form from the patient or legal guardian. - No age restrictions. Who Should NOT Join This Trial: - Patients whose extreme hypertriglyceridemia is caused by alcohol abuse, uncontrolled diabetes, or other medical conditions, unless extreme hypertriglyceridemia is confirmed after controlling the underlying condition. - Lack of willing to sign a consent form. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Patients with extreme hypertriglyceridemia (triglyceride levels ≥10 mmol/L), confirmed by at least two independent measurements. * Written informed consent from the patient or legal guardian. * No age restrictions. Exclusion Criteria: * Patients whose extreme hypertriglyceridemia is caused by alcohol abuse, uncontrolled diabetes, or other medical conditions, unless extreme hypertriglyceridemia is confirmed after controlling the underlying condition. * Lack of informed consent.

Locations (6)

Astrakhan State Medical University
Astrakhan, Russia
Chelyabinsk State Medical Academy
Chelyabinsk, Russia
Kaluga City Clinical Hospital No. 5
Kaluga, Russia
State Medical University
Kazan', Russia
National Medical Research Center of Cardiology Named after Academician E.I. Chazov
Moscow, Russia
Research Centre for Medical Genetics
Moscow, Russia